Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on October 21, 2010. The filing details the entry into material definitive agreements to secure funding for the company's G protein-coupled receptor (GPCR) program, a core component of its life sciences research and development efforts.
Key Financial Metrics and Agreements
- Development Funding (Vulcan Agreement): Received an immediate payment of $20 million from Vulcan Inc. and Cougar Investment Holdings LLC. In exchange, Omeros agreed to pay tiered percentages of net proceeds from the GPCR program. The blended rate is in the mid-teens for the first ~$1.5 billion in cumulative net proceeds, dropping to 1% thereafter.
- Grant Award (LSDF Agreement): Received a $5 million grant from the Life Sciences Discovery Fund Authority (LSDF) of Washington State. Similar to the Vulcan Agreement, Omeros must pay tiered percentages of net proceeds from the GPCR program.
- Debt Financing (Oxford Loan Agreement): Entered a loan facility with Oxford Finance Corporation for up to $20 million in two tranches.
- Tranche 1: $10 million borrowed immediately. Approximately $9 million was used to repay prior debt to BlueCrest Venture Finance Master Fund Limited in full.
- Tranche 2: $10 million available at Omeros' option before March 31, 2011, subject to conditions.
- Interest Rates: Tranche 1 accrues at a fixed 8.55% annually. Tranche 2 (if borrowed) will accrue at 3-month LIBOR + 8.25%.
- Repayment: Interest-only payments through October 31, 2011. Principal and interest payable monthly thereafter, with a maturity date of October 21, 2014.
- Fees: $50,000 facility fee per tranche. A final payment fee of 5% of the principal amount is due upon maturity or prepayment.
- Equity Issuance: Issued three unregistered warrants to Vulcan to purchase a total of 399,999 shares of common stock (133,333 shares per warrant) at exercise prices of $20.00, $30.00, and $40.00, respectively. Warrants are exercisable for five years.
- Asset Acquisition: Agreed to purchase intellectual property assets from Patobios Limited for $7.8 million CAD in cash and $3.0 million CAD in Omeros common stock.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or revenue/profit metrics for the prior period. However, the material changes include:
- Liquidity Improvement: Immediate cash inflow of $20 million from Vulcan and $5 million in grant funding (to be paid against expenses), plus $10 million from the Oxford loan.
- Debt Restructuring: Full repayment and termination of the prior loan agreement with BlueCrest Venture Finance Master Fund Limited.
- Capital Structure: Introduction of new secured debt obligations and the issuance of equity warrants.
Outlook, Risks, and Contingencies
- Performance Obligations: Omeros must use commercially reasonable efforts to screen a majority of known human Class A orphan GPCRs within 19 months and commence medicinal chemistry efforts for one product candidate.
- Security Interests: Omeros granted a security interest in personal property related to the GPCR program to Vulcan (junior to other financing) and a security interest in substantially all assets (excluding IP) to Oxford.
- Default Risks: Both the Vulcan and Oxford agreements contain customary events of default, including non-payment, bankruptcy, and material adverse changes. Default could trigger acceleration of debt or cessation of funding.
- Change of Control: The agreements allow for change in control transactions if the agreements are assigned to the counterparty, though consideration from such transactions is excluded from net proceeds calculations.
- Term: The Vulcan and LSDF agreements have a base term of 35 years, automatically extending until cumulative net proceeds reach approximately $1.5 billion.
Investor Verification Checklist
- Verify the exact amount of the $5 million LSDF grant received to date versus the total award.
- Confirm the status of the $7.8 million CAD cash and $3.0 million CAD stock payment to Patobios Limited.
- Monitor the conditions precedent required to draw the second $10 million tranche from Oxford Finance Corporation.
- Review the specific definition of "net proceeds" in the agreements to understand future royalty obligations.
- Check for any subsequent filings regarding the exercise of the warrants issued to Vulcan.